About this trial

The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • 18F-MFBG
  • 68Ga-Dotatate

Treatment groups

150 Participants
are divided into 1 treatment group

Locations

1
Peking union medical college hospital100010, BeijingDongcheng, China

Sponsors and collaborators

Peking Union Medical College Hospital

Lead sponsor